SOLIGENIX, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3851 USD | -1.26% |
|
-3.46% | -49.14% |
Presenter SpeechOreola Donini (Executives)Good day, everyone. It's very nice to be here, and I...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.39
USD
Average target price
2.5
USD
Spread / Average Target
+541.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -49.14% | 5.55M | |
| +9.14% | 114B | |
| +11.55% | 104B | |
| -13.43% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -3.74% | 17.89B | |
| +7.91% | 14.28B | |
| +34.87% | 12.55B |
- Stock Market
- Equities
- SNGX Stock
- News Soligenix, Inc.
- Transcript : Soligenix, Inc. Presents at MedInvest Infectious Disease and Immunology Investor Conference, Jun-16-2020 02
